The Rosuvastatin case is that rare beast – a decision of a 5 member Full Bench of the Federal Court. It canvases many issues and, no doubt, we shall be picking over it for years to come. Susan Gatford, at the Victorian Bar, has kindly provided a guest post on the section 40 issues.
The 5 member Full Bench of the Federal Court has dismissed AstraZeneca’s appeal in the “rosuvastatin” case.
IP Australia has published a report on patent pendency in Australia
The Full Court has held an exclusive licensee bound to keep paying costs of patent litigation even after the licence expired
ACIP’s final report into Innovation Patents has been published.
The US Supreme Court has unanimously ruled that Alice Corporation’s claim to patent a computer-implemented method and system for exchanging obligations is not patentable subject matter under US law:
The High Court has granted special leave to Aspen Pharma to appeal from the Full Federal Court’s decision to allow Lundbeck to apply to extend the term of its patent 10 years late. The High Court was not interested at all in the exercise of the discretion to allow a 10 year extension. the question is whether a power to extend time exists at all.
Jessup J has upheld the rejection of a patent for an auscultative method on grounds the claimed invention was insufficiently clearly disclosed.
The ACCC has sued Pfizer for alleged antitrust breaches by locking in Lipitor sales for 12 months after the patent expired
Yesterday, the US Supreme Court heard oral arguments on the patentability of Alice Corporation’s payment system.